Power, Robert F.
Doherty, Damien E.
Horgan, Roberta
Fahey, Pat
Gallagher, David J.
Lowery, Maeve A.
Cadoo, Karen A.
Funding for this research was provided by:
NDTP academic track internship programme
Article History
Received: 10 March 2024
Accepted: 14 May 2024
First Online: 14 June 2024
Declarations
:
: Ethical approval was granted from St James’s Hospital/Tallaght University Hospital Research Ethics Committee (ID 2128).
: Not applicable.
: Damien E. Doherty, Stock and Other Ownership Interests: Inovio Pharmaceuticals; David J. Gallagher, Research Funding: Pfizer (Inst), Travel, Accommodations, Expenses: Roche, Servier; Maeve A. Lowery, Consulting or Advisory Role: Roche/Genentech, AstraZeneca, Servier, Research Funding: MSD, Exelixis, Basilea, Astellas Pharma; Karen A. Cadoo, Honoraria: Pfizer, Roche Ireland, Consulting or Advisory Role: Astra Zeneca, MSD, GlaxoSmithKline, NextCure, Eisai; Research Funding: MSD (Inst), Immunogen (Inst), The Irish Cancer Society (Inst), Travel, Accommodations, Expenses: Roche No other potential conflicts of interest were reported.